AZD 4017 is a selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that has been investigated for its potential in treating metabolic disorders. It is primarily studied for its role in reducing cortisol levels within tissues such as liver and adipose tissue, where 11β-HSD1 is highly expressed. By inhibiting this enzyme, AZD 4017 helps lower local cortisol exposure, which may improve insulin sensitivity and glucose metabolism.

It has been evaluated in clinical trials for conditions like type 2 diabetes and non-alcoholic fatty liver disease (NAFLD), aiming to address underlying metabolic dysfunction. Additionally, due to cortisol’s influence on weight regulation and lipid metabolism, AZD 4017 has been explored for potential benefits in obesity-related complications. Its development reflects a targeted approach to modulating tissue-specific cortisol activity without affecting systemic adrenal function.